4basebio

Update in progress

4BB.L (LSE)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

4basebio PLC and its subsidiaries develop and commercialize synthetic DNA and RNA products and non-viral vector solutions for research and therapeutics worldwide. Its portfolio includes hpDNA (hairpin-ended linear dsDNA for viral and non-viral delivery), opDNA (partially opened dsDNA for in vitro transcription), oeDNA (open-ended dsDNA for genome editing), osDNA (modified backbone for immune tuning in DNA vaccines), and The Hermes delivery platform. Founded 2008, formerly 4basebio UK Societas, renamed 2021, based in Cambridge, UK.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.16; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.23; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive